Skip to main content

Advertisement

Table 4 Suggestion for the use of G-CSFs in individual cases. Primary prevention dosage of G-CSFs

From: A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

  Q16. TC for breast cancera Q17. CDDP + S-1 for gastric cancerb Q18. FOLFOXIRI for colorectal cancerc
  n = 145 n = 187 n = 183
I recommend of primary prophylactic administration of G-CSFs 43 (29.7)d 1 (0.5) 23 (12.6)
After Grade 4 neutropenia developed, I recommend G-CSFs 48 (33.1) 63 (33.7) 70 (38.2)
After FN developed, I recommend G-CSFs 54 (37.2) 66 (35.3) 56 (30.6)
I do not recommend G-CSFs 0 (0.0) 57 (30.5) 34 (18.6)
  1. TC Docetaxel and Cyclophosphamide, CDDP Cisplatin, S-1 Tegafur, gimeracil, and oteracil, FOLFOXIRI Irinotecan, oxaliplatin, and 5-fluorouracil, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
  2. aA 67-year-old woman. You plan to treat with TC therapy (docetaxel 75 mg / m2 and cyclophosphamide 600 mg / m2, administered every 3 weeks) as postoperative chemotherapy for breast cancer. What kind of suggestion do you do as a pharmacist?
  3. bA 70-year-old man. As first-line chemotherapy for unresectable gastric cancer, you plan to treat with S-1 and cisplatin combination therapy. What kind of suggestion do you do as a pharmacist?
  4. cA 70-year-old woman. You plan to treat with irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) therapy as first-line chemotherapy for unresectable colon cancer. What kind of suggestion do you do as a pharmacist?
  5. dNumber (percent)